-
公开(公告)号:WO9805292A3
公开(公告)日:1998-04-02
申请号:PCT/US9713383
申请日:1997-08-06
Applicant: SCHERING CORP
Inventor: LOWE DEREK B , CHANG WEI K , KOZLOWSKI JOSEPH A , BERGER JOEL G , MCQUADE ROBERT , BARNETT ALLEN , SHERLOCK MARGARET , TOM WING , DUGAR SUNDEEP , CHEN LIAN-YONG , CLADER JOHN W , CHACKALAMANNIL SAMUEL , WANG YUGUANG , MCCOMBIE STUART W , TAGAT JAYARAM R , VICE SUSAN F , VACCARO WAYNE D , GREEN MICHAEL J , BROWNE MARGARET E , ASBEROM THEODROS , BOYLE CRAIG D , JOSIEN HUBERT B
IPC: C07D211/58 , A61K31/00 , A61K31/435 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/501 , A61K45/00 , A61P25/28 , C07D211/24 , C07D211/32 , C07D211/96 , C07D239/34 , C07D257/04 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , A61K
CPC classification number: C07D405/14 , C07C2601/14 , C07D211/24 , C07D211/32 , C07D239/34 , C07D257/04 , C07D295/03 , C07D295/088 , C07D295/092 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D405/12 , C07D409/14
Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperidine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R?1, R2, R3, R4, R21, R27, R28¿, X, Y and Z as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.
Abstract translation: 根据式I的二-N-取代哌嗪或1,4-二取代哌嗪化合物(包括所有异构体,盐,酯和溶剂合物),其中R,R 1,R 2,R 3,R 4,R 21,R 27,R 28,X Y和Z如本文所定义的是可用于治疗认知障碍如阿尔茨海默氏病的毒蕈碱拮抗剂。 还公开了药物组合物和制备方法。 还公开了上式化合物与乙酰胆碱酯酶抑制剂的协同组合。
-
公开(公告)号:JP2009040778A
公开(公告)日:2009-02-26
申请号:JP2008194199
申请日:2008-07-28
Applicant: Schering Corp , シェーリング コーポレイションSchering Corporation
Inventor: KOZLOWSKI JOSEPH A , LOWE DEREK B , CHANG WEI K , DUGAR SUNDEEP
IPC: C07D211/58 , C07D295/08 , A61K31/445 , A61K31/4545 , A61K31/495 , A61K31/496 , A61K31/505 , A61K31/506 , A61P25/28 , A61P43/00 , C07D239/34 , C07D241/04 , C07D295/088 , C07D295/096 , C07D311/68 , C07D317/58 , C07D317/62 , C07D405/14
CPC classification number: C07D317/62 , C07B2200/07 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/12 , C07D211/58 , C07D239/34 , C07D295/088 , C07D295/096 , C07D311/68 , C07D317/58
Abstract: PROBLEM TO BE SOLVED: To provide a muscarinic antagonist.
SOLUTION: A di-N-substituted piperazine compound or a 1,4-substituted piperazine compound in accordance with formula (I) is a muscarinic antagonist useful to treat cognitive disorders such as Alzheimer's disease. A synergistic combination of a compound of the above formula with an acetylcholine esterase inhibitor is also disclosed.
COPYRIGHT: (C)2009,JPO&INPITAbstract translation: 要解决的问题:提供毒蕈碱拮抗剂。 解决方案:根据式(I)的二-N-取代的哌嗪化合物或1,4-取代的哌嗪化合物是用于治疗认知障碍如阿尔茨海默氏病的毒蕈碱拮抗剂。 还公开了上式化合物与乙酰胆碱酯酶抑制剂的协同组合。 版权所有(C)2009,JPO&INPIT
-
3.
公开(公告)号:JP2008024714A
公开(公告)日:2008-02-07
申请号:JP2007233458
申请日:2007-09-07
Applicant: Schering Corp , シェーリング コーポレイションSchering Corporation
Inventor: LOWE DEREK , WEI CHANG , KOZLOWSKI JOSEPH , BERGER JOEL G , MCQUADE ROBERT , BARNETT ALLEN , SCHERLOCK MARGARET , TOM WING , DUGAR SUNDEEP , CHEN LIAN-YONG , CLADER JOHN W , CHACKALAMANNIL SAMUEL , WANG YUGUANG , MCCOMBIE STUART W , TAGAT JAYARAM R , VICE SUSAN F , WAYNE VACCARO , GREEN MICHAEL J , BROWNE MARGARET E , ASBEROM THEODROS
IPC: C07D211/20 , C07D295/08 , A61K31/335 , A61K31/357 , A61K31/36 , A61K31/365 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4468 , A61K31/451 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/549 , A61P25/00 , A61P25/28 , C07D211/14 , C07D211/22 , C07D211/24 , C07D211/26 , C07D211/32 , C07D211/58 , C07D211/62 , C07D213/65 , C07D213/70 , C07D233/84 , C07D237/10 , C07D239/34 , C07D241/04 , C07D241/18 , C07D257/04 , C07D263/58 , C07D271/06 , C07D277/20 , C07D277/34 , C07D285/34 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/12 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/14 , C07D295/145 , C07D295/15 , C07D307/33 , C07D309/12 , C07D317/28 , C07D317/62 , C07D333/20 , C07D335/02 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14
CPC classification number: C07D211/20 , C07C2601/14 , C07D211/22 , C07D211/24 , C07D211/32 , C07D211/58 , C07D213/643 , C07D213/65 , C07D213/68 , C07D237/14 , C07D239/34 , C07D239/38 , C07D257/04 , C07D277/34 , C07D295/03 , C07D295/088 , C07D295/092 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D295/26 , C07D307/33 , C07D333/20 , C07D335/02 , C07D405/12 , C07D405/14 , C07D409/14
Abstract: PROBLEM TO BE SOLVED: To provide muscarinic antagonists useful for treating cognitive disorders. SOLUTION: The di-N-substituted piperidine compound or 1,4-di-substituted piperazine compound of formula (I) (R, R 1 , R 2 , R 3 , R 4 , R 21 , R 27 , R 28 , X, Y, and Z are particularly defined) (including all isomers, salts, esters, and solvates) are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors. COPYRIGHT: (C)2008,JPO&INPIT
Abstract translation: 要解决的问题:提供可用于治疗认知障碍的毒蕈碱拮抗剂。 解决方案:式(I)的二-N-取代的哌啶化合物或1,4-二取代哌嗪化合物(R,R 1,R 2,R 2, ,R
3 SP>,R 4 SP>,R 21 SP>,R SP SP 27, ,X,Y和Z特别定义)(包括所有异构体,盐,酯和溶剂合物)是可用于治疗认知障碍如阿尔茨海默氏病的毒蕈碱拮抗剂。 还公开了药物组合物和制备方法。 还公开了上述化合物或能够与乙酰胆碱酯酶抑制剂一起增强乙酰胆碱释放的其它化合物的协同组合。 版权所有(C)2008,JPO&INPIT -
4.
公开(公告)号:WO9626196A3
公开(公告)日:1996-10-03
申请号:PCT/US9601532
申请日:1996-02-16
Applicant: SCHERING CORP
Inventor: LOWE DEREK , CHANG WEI , KOZLOWSKI JOSEPH , BERGER JOEL G , MCQUADE ROBERT , BARNETT ALLEN , SCHERLOCK MARGARET , TOM WING , DUGAR SUNDEEP , CHEN LIAN-YONG , CLADER JOHN W , CHACKALAMANNIL SAMUEL
IPC: C07D295/08 , A61K31/335 , A61K31/357 , A61K31/36 , A61K31/365 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4468 , A61K31/451 , A61K31/495 , A61K31/496 , A61K31/505 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61P25/28 , C07D211/14 , C07D211/22 , C07D211/24 , C07D211/26 , C07D211/32 , C07D211/58 , C07D211/62 , C07D239/34 , C07D257/04 , C07D271/06 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/12 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/14 , C07D295/145 , C07D295/15 , C07D307/33 , C07D309/12 , C07D317/28 , C07D317/62 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , A61K31/449 , C07D401/10 , C07D403/10 , C07D407/04 , C07D413/10
CPC classification number: C07D211/20 , C07C2601/14 , C07D211/22 , C07D211/24 , C07D211/32 , C07D211/58 , C07D213/643 , C07D213/65 , C07D213/68 , C07D237/14 , C07D239/34 , C07D239/38 , C07D257/04 , C07D277/34 , C07D295/03 , C07D295/088 , C07D295/092 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D295/26 , C07D307/33 , C07D333/20 , C07D335/02 , C07D405/12 , C07D405/14 , C07D409/14
Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula (I) (including all isomers, salts, esters, and solvates) wherein R, R?1, R2, R3, R4, R21, R27, R28¿, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhan cing acetylcholine release with acetylcholinesterase inhibitors.
Abstract translation: 根据式I的二-N-取代哌嗪或1,4-二取代哌嗪化合物(包括所有异构体,盐,酯和溶剂合物),其中R,R 1,R 2,R 3,R 4,R 21,R 27,R 28,X Y和Z如本文所定义的是可用于治疗认知障碍如阿尔茨海默氏病的毒蕈碱拮抗剂。 还公开了药物组合物和制备方法。 还公开了上述化合物或能够与乙酰胆碱酯酶抑制剂一起增强乙酰胆碱释放的其它化合物的协同组合。
-
公开(公告)号:CA2212895C
公开(公告)日:2007-04-10
申请号:CA2212895
申请日:1996-02-16
Applicant: SCHERING CORP
Inventor: TAGAT JAYARAM R , LOWE DEREK , CHANG WEI , KOZLOWSKI JOSEPH , BERGER JOEL G , CHACKALAMANNIL SAMUEL , VACCARO WAYNE , CLADER JOHN W , CHEN LIAN-YONG , MCCOMBIE STUART W , DUGAR SUNDEEP , ASBEROM THEODROS , BARNETT ALLEN , TOM WING , SHERLOCK MARGARET , MCQUADE ROBERT , GREEN MICHAEL J , VICE SUSAN F , WANG YUGUANG , BROWNE MARGARET E
IPC: C07D295/08 , C07D295/096 , A61K31/335 , A61K31/357 , A61K31/36 , A61K31/365 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4468 , A61K31/451 , A61K31/495 , A61K31/496 , A61K31/505 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/695 , A61P25/28 , C07D211/14 , C07D211/22 , C07D211/24 , C07D211/26 , C07D211/32 , C07D211/58 , C07D211/62 , C07D213/63 , C07D213/70 , C07D233/84 , C07D237/14 , C07D239/32 , C07D239/34 , C07D241/18 , C07D257/04 , C07D263/58 , C07D271/06 , C07D277/34 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/108 , C07D295/112 , C07D295/116 , C07D295/12 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/14 , C07D295/145 , C07D295/15 , C07D307/33 , C07D309/12 , C07D317/28 , C07D317/62 , C07D333/20 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07F7/10
Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula (I) (including all isomers salts esters, and solvates) wherein R, R1, R2, R3, R4, R21, R27, R28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhan cing acetylcholine release with acetylcholinesterase inhibitors.
-
公开(公告)号:CA2261725C
公开(公告)日:2005-10-25
申请号:CA2261725
申请日:1997-08-06
Applicant: SCHERING CORP
Inventor: BARNETT ALLEN , SHERLOCK MARGARET , MCQUADE ROBERT , VICE SUSAN F , GREEN MICHAEL J , WANG YUGUANG , BERGER JOEL G , TOM WING , ASBEROM THEODROS , BROWNE MARGARET E , BOYLE CRAIG D , JOSIEN HUBERT B , DUGAR SUNDEEP , KOZLOWSKI JOSEPH A , CLADER JOHN W , MCCOMBIE STUART W , LOWE DEREK B , TAGAT JAYARAM R , CHEN LIAN-YONG , CHACKALAMANNIL SAMUEL , CHANG WEI K , VACCARO WAYNE D
IPC: C07D211/58 , A61K31/00 , A61K31/435 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/501 , A61K45/00 , A61P25/28 , C07D211/24 , C07D211/32 , C07D211/96 , C07D239/34 , C07D257/04 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/53
Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperidine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R1, R2, R3, R4, R21, R22, R28, X, Y and Z a s defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.
-
公开(公告)号:AT258170T
公开(公告)日:2004-02-15
申请号:AT96906286
申请日:1996-02-16
Applicant: SCHERING CORP
Inventor: LOWE DEREK , CHANG WEI , KOZLOWSKI JOSEPH , BERGER JOEL G , MCQUADE ROBERT , BARNETT ALLEN , SCHERLOCK MARGARET , TOM WING , DUGAR SUNDEEP , CHEN LIAN-YONG , CLADER JOHN W , CHACKALAMANNIL SAMUEL , MCCOMBIE STUART W , TAGAT JAYARAM R , VICE SUSAN F , VACCARO WAYNE , WANG YUGUANG , GREEN MICHAEL J , BROWNE MARGARET E , ASBEROM THEODROS
IPC: C07D295/08 , A61K31/335 , A61K31/357 , A61K31/36 , A61K31/365 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4468 , A61K31/451 , A61K31/495 , A61K31/496 , A61K31/505 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61P25/28 , C07D211/14 , C07D211/22 , C07D211/24 , C07D211/26 , C07D211/32 , C07D211/58 , C07D211/62 , C07D239/34 , C07D257/04 , C07D271/06 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/12 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/14 , C07D295/145 , C07D295/15 , C07D307/33 , C07D309/12 , C07D317/28 , C07D317/62 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D401/10 , C07D403/10 , C07D407/04
Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R1, R2, R3, R4, R21, R27, R28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors.
-
公开(公告)号:DE69905248T2
公开(公告)日:2004-01-29
申请号:DE69905248
申请日:1999-06-07
Applicant: SCHERING CORP
Inventor: DUGAR SUNDEEP , NEUSTADT R , STAMFORD W , WU YUSHENG
IPC: C07D295/12 , A61K31/10 , A61K31/167 , A61K31/17 , A61K31/18 , A61K31/4164 , A61K31/438 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/445 , A61K31/4468 , A61K31/451 , A61K31/47 , A61K31/472 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/54 , A61K31/55 , A61P3/04 , A61P3/10 , C07C233/25 , C07C233/29 , C07C275/30 , C07C275/32 , C07C275/34 , C07C275/38 , C07C311/05 , C07C323/29 , C07C323/32 , C07C323/39 , C07C323/41 , C07C323/44 , C07D211/26 , C07D211/58 , C07D211/60 , C07D211/96 , C07D213/40 , C07D213/74 , C07D213/75 , C07D215/08 , C07D217/06 , C07D223/04 , C07D223/22 , C07D233/64 , C07D295/14 , C07D295/20 , C07D295/215 , C07D491/113 , C07D498/10 , C07C321/02 , C07C311/00
Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein a and b are 0-2, provided that the sum is 0-3; Q is (i) or (-N=); X is -O-, -S-, -SO-, -SO2-, -CH(OR )-, -C(O)-, -C(R )2-, optionally substituted alkenyl, alkynyl or (ii); R is optionally substituted aryl, heteroaryl, substituted amino, alkyl-OC(O)R , aryloxyalkyl, (iii) wherein m is 1-4, or (iv) wherein d and e are 0-2; R , R , R and R are H, alkyl, optionally substituted cycloalkyl, halogen, -OR , -N(R )2, -CO2R or CF3; R and R are H, alkyl, alkenyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, cycloalkyl or cycloalkylalkyl, or R and R , form a 3-7-membered carbocyclic ring, or a 4-7-membered heterocyclic ring; R is H, alkyl, cycloalkyl, optionally substituted aryl or heteroaryl; R is alkyl, cycloalkyl, optionally substituted aryl or heteroaryl; R is H, alkyl or cycloalkyl; and R is R or halogen; are claimed, as well as additional novel compounds; also claimed are pharmaceutical compositions and methods of using said novel compounds in the treatment of eating disorders and diabetes.
-
公开(公告)号:HU221309B1
公开(公告)日:2002-09-28
申请号:HU9602616
申请日:1995-03-22
Applicant: SCHERING CORP
Inventor: DUGAR SUNDEEP , KIRKUP MICHAEL P , SHANKAR BANDERPALLE
IPC: A61K31/395 , A61K31/397 , A61P3/06 , A61P9/10 , C07B53/00 , C07C227/32 , C07C229/34 , C07C311/06 , C07C311/19 , C07C311/37 , C07C319/20 , C07C323/62 , C07D205/08
Abstract: Substituted azetidinone hypocholesterolemic agents of the formula or a pharmaceutically acceptable salt thereof, wherein: Ar1 is R3-substituted aryl; Ar2 is R4-substituted aryl; Ar3 is R5-substituted aryl; Y and Z are independently -CH2-, -CH(lower alkyl)- or -C(dilower alkyl)-; A is -O-, -S-, -S(O)- or -S(O)2-; R1 is -OR6, -O(CO)R6, -O(CO)OR9 or -O(CO)NR6R7; R2 is hydrogen, lower alkyl or aryl; or R1 and R2 together are =O; q is 1, 2 or 3; p is 0, 1,2, 3 or 4; R5 is 1-3 substitutes independently selected from -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR9, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2-lower alkyl, -NR6SO2-aryl, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2-alkyl, S(O)0-2-aryl, -O(CH2)1-10-COOR6, -O(CH2)0-10CONR6R7, o-halogeno, m-halogeno, o-lower alkyl, m-lower alkyl, -(lower alkylene)-COOR6 and -CH=CH-COOR6; R3 and R4 are 1-3 substituents independently selected from R5, hydrogen, p-lower alkyl, aryl, -NO2, CF3 and p-halogeno; R6, R7 and R8 are hydrogen, lower alkyl, aryl or aryl-substituted lower alkyl; and R9 is lower alkyl, aryl or aryl-substituted lower alkyl; are disclosed, as well as a method of lowering serum cholesterol by administering said compounds, pharmaceutical compositions containing them, the combination of a substituted azetidinone and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis, novel intermediates and methods for preparing said intermediates.
-
公开(公告)号:DK0792264T3
公开(公告)日:2002-04-22
申请号:DK95939677
申请日:1995-11-15
Applicant: SCHERING CORP
Inventor: BURNETT DUANE A , DUGAR SUNDEEP , MCKITTRICK BRIAN A
IPC: A61K31/395 , A61K31/397 , A61K31/44 , A61K31/4427 , A61K31/4433 , A61P3/06 , A61P9/10 , C07D205/08 , C07D401/12 , C07D409/12
Abstract: Sulfur-substituted azetidinone hypocholesterolemic agents of the formula I or a pharmaceutically acceptable salt thereof, wherein: Ar1 is aryl, R10-substituted aryl or heteroaryl; Ar2 is aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X and Y are -CH2-, -CH(lower alkyl)- or -C(dilower alkyl)-; R is -OR6, -O(CO)R6, -O(CO)OR9 or -O(CO)NR6R7; R1 is hydrogen, lower alkyl or aryl; or R and R1 together are =O; q is 0 or 1; r is 0, 1 or 2; m and n are 0-5; provided that the sum of m, n and q is 1-5; R4 is selected from lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -(lower alkylene)-COOR6 and -CH=CH-COOR6; R5 is selected from -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -CF3, -CN, -NO2, halogen, -(lower alkylene)COOR6 and -CH=CH-COOR6; R6, R7 and R8 are H, lower alkyl, aryl or aryl-substituted lower alkyl; R9 is lower alkyl, aryl or aryl-substituted lower alkyl; and R10 is selected from lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH2)1-5OR6, -O(CO)NR6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO2R9, -COOR6, -CONR6R7, -COR6, -SO2NR6R7, S(O)0-2R9, -O(CH2)1-10-COOR6, -O(CH2)1-10CONR6R7, -CF3, -CN, -NO2 and halogen; are disclosed, as well as pharmaceutical compositions containing them, and a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor.
-
-
-
-
-
-
-
-
-